Quiros Juan Jose Chacon Sells 105,000 Shares of Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the transaction, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, May 4th, Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock. The stock was sold at an average price of $70.48, for a total value of $546,290.48.
• On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The stock was sold at an average price of $70.78, for a total transaction of $4,759,884.22.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The shares were sold at an average price of $66.26, for a total value of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total value of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The shares were sold at an average price of $60.08, for a total value of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Stock Performance

NASDAQ:ESTA traded down $0.26 during trading hours on Friday, reaching $71.77. 347,333 shares of the company’s stock were exchanged, compared to its average volume of 520,839. The company has a 50-day moving average of $65.27 and a 200 day moving average of $66.59. Establishment Labs Holdings Inc. has a 1-year low of $33.30 and a 1-year high of $83.31. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -48.17 and a beta of 1.12.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 202.78% and a negative net margin of 19.05%.The company had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same period in the prior year, the business earned ($0.70) EPS. The business’s quarterly revenue was up 44.7% compared to the same quarter last year. Research analysts anticipate that Establishment Labs Holdings Inc. will post -0.86 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ESTA. Stephens raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Mizuho raised their price target on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. BTIG Research lifted their price target on Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Canaccord Genuity Group increased their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $87.14.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC boosted its stake in shares of Establishment Labs by 11.1% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after acquiring an additional 197,962 shares in the last quarter. Bamco Inc. NY increased its stake in Establishment Labs by 30.2% in the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares in the last quarter. Tyro Capital Management LLC raised its holdings in Establishment Labs by 1.0% during the third quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock worth $44,165,000 after purchasing an additional 10,735 shares during the last quarter. William Blair Investment Management LLC raised its holdings in Establishment Labs by 17.6% during the third quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock worth $41,709,000 after purchasing an additional 152,299 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Establishment Labs by 117.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock worth $59,145,000 after purchasing an additional 438,206 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.